IBI310 is named as an intervention in 10 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Tianjin Medical University Cancer Institute and Hospital (2). The most-studied condition is Hepatocellular Carcinoma (HCC).
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hepatocellular Carcinoma (HCC) | 2 |
| BRAF V600E | 1 |
| Colorectal Cancer | 1 |
| Sintilimab | 1 |
| MSS (Microsatellite Stable) | 1 |
| Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | 1 |
| Pancreatic Cancer | 1 |
| HCC - Hepatocellular Carcinoma | 1 |
| Conversion Therapy | 1 |
| Cholangiocarcinoma, Intrahepatic | 1 |
| PD-L1 | 1 |
| CTLA4 | 1 |
| NSCLC Stage II | 1 |
| NSCLC Stage III | 1 |
| Non Small Cell Lung Cancer | 1 |
| Neuroendocrine Neoplasm | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 10 | 7 |
A trial with sites in more than one country appears in each of those registers.
10 current trials in our China register name IBI310 (also registered as Ipilimumab N01) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 10 trials are recruiting: 7 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tianjin Medical University Cancer Institute and Hospital (2), Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD (2), Shanghai Pulmonary Hospital, Shanghai, China (2) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI310 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IBI310 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI310 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.